Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Lantto

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Current Pharmaceutical Design|June 22, 2006
Recombinant human polyclonal antibodies: A new class of therapeutic antibodies against viral infectionsSøren Bregenholt, Allan Jensen, Johan Lantto, et al.
International Journal of Cancer|June 26, 2016
Pan-HER-An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimersSofie Ellebaek, Susanne Brix, Michael Grandal, et al.
Antiviral Research|September 16, 2021
A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challengeScott Parker, June D'Angelo, R Mark Buller, et al.
Breast Cancer Research : BCR|May 17, 2020
Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXsTejaswini P Reddy, Dong S Choi, Ann C Anselme, et al.
Journal of Virology|December 15, 2010
Capturing the natural diversity of the human antibody response against vaccinia virusJohan Lantto, Margit Haahr Hansen, Søren Kofoed Rasmussen, et al.
Oncotarget|October 14, 2015
In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomographyCarsten H Nielsen, Mette M Jensen, Lotte K Kristensen, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 14, 2026
Inhibition of cytomegalovirus reactivation by ex vivo treatment of human kidneys with the SYN002 immunotoxinEmma Poole, Sarah Hosgood, Erica Appiah, et al.
Theranostics|November 23, 2019
CD4<sup>+</sup> and CD8a<sup>+</sup> PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer modelsLotte K Kristensen, Camilla Fröhlich, Camilla Christensen, et al.
Molecular Cancer Therapeutics|January 24, 2015
Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab ResistanceMikkel W Pedersen, Helle J Jacobsen, Klaus Koefoed, et al.
Journal of Virology|July 1, 2011
Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organsMarina Zaitseva, Senta M Kapnick, Clement A Meseda, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Current Pharmaceutical Design|June 22, 2006
Recombinant human polyclonal antibodies: A new class of therapeutic antibodies against viral infectionsSøren Bregenholt, Allan Jensen, Johan Lantto, et al.
International Journal of Cancer|June 26, 2016
Pan-HER-An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimersSofie Ellebaek, Susanne Brix, Michael Grandal, et al.
Antiviral Research|September 16, 2021
A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challengeScott Parker, June D'Angelo, R Mark Buller, et al.
Breast Cancer Research : BCR|May 17, 2020
Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXsTejaswini P Reddy, Dong S Choi, Ann C Anselme, et al.
Journal of Virology|December 15, 2010
Capturing the natural diversity of the human antibody response against vaccinia virusJohan Lantto, Margit Haahr Hansen, Søren Kofoed Rasmussen, et al.
Oncotarget|October 14, 2015
In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomographyCarsten H Nielsen, Mette M Jensen, Lotte K Kristensen, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 14, 2026
Inhibition of cytomegalovirus reactivation by ex vivo treatment of human kidneys with the SYN002 immunotoxinEmma Poole, Sarah Hosgood, Erica Appiah, et al.
Theranostics|November 23, 2019
CD4<sup>+</sup> and CD8a<sup>+</sup> PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer modelsLotte K Kristensen, Camilla Fröhlich, Camilla Christensen, et al.
Molecular Cancer Therapeutics|January 24, 2015
Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab ResistanceMikkel W Pedersen, Helle J Jacobsen, Klaus Koefoed, et al.
Journal of Virology|July 1, 2011
Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organsMarina Zaitseva, Senta M Kapnick, Clement A Meseda, et al.
Pageof 4